Author: Kassavou, Aikaterini; Mirzaei, Venus; Shpendi, Sonia; Brimicombe, James; Chauhan, Jagmohan; Bhattacharya, Debi; Naughton, Felix; Hardeman, Wendy; Eborall, Helen; Van Emmenis, Miranda; De Simoni, Anna; Takhar, Amrit; Gupta, Pankaj; Patel, Prashanth; Mascolo, Cecilia; Prevost, Andrew Toby; Morris, Stephen; Griffin, Simon; McManus, Richard J.; Mant, Jonathan; Sutton, Stephen
Title: The feasibility of the PAM intervention to support treatment-adherence in people with hypertension in primary care: a randomised clinical controlled trial Cord-id: xq0fu9sg Document date: 2021_4_26
ID: xq0fu9sg
Snippet: The PAM intervention is a behavioural intervention to support adherence to anti-hypertensive medications and therefore to lower blood pressure. This feasibility trial recruited 101 nonadherent patients (54% male, mean age 65.8 years) with hypertension and high blood pressure from nine general practices in the UK. The trial had 15.5% uptake and 7.9% attrition rate. Patients were randomly allocated to two groups: the intervention group (n = 61) received the PAM intervention as an adjunct to usual
Document: The PAM intervention is a behavioural intervention to support adherence to anti-hypertensive medications and therefore to lower blood pressure. This feasibility trial recruited 101 nonadherent patients (54% male, mean age 65.8 years) with hypertension and high blood pressure from nine general practices in the UK. The trial had 15.5% uptake and 7.9% attrition rate. Patients were randomly allocated to two groups: the intervention group (n = 61) received the PAM intervention as an adjunct to usual care; the control group (n = 40) received usual care only. At 3 months, biochemically validated medication adherence was improved by 20% (95% CI 3–36%) in the intervention than control, and systolic blood pressure was reduced by 9.16 mmHg (95% CI 5.69–12.64) in intervention than control. Improvements in medication adherence and reductions in blood pressure suggested potential intervention effectiveness. For a subsample of patients, improvements in medication adherence and reductions in full lipid profile (cholesterol 1.39 mmol/mol 95% CI 0.64–1.40) and in glycated haemoglobin (3.08 mmol/mol, 95% CI 0.42–5.73) favoured the intervention. A larger trial will obtain rigorous evidence about the potential clinical effectiveness and cost-effectiveness of the intervention. Trial registration Trial date of first registration 28/01/2019. ISRCTN74504989. https://doi.org/10.1186/ISRCTN74504989.
Search related documents:
Co phrase search for related documents- additional information and adherence improve: 1
Co phrase search for related documents, hyperlinks ordered by date